SLC4A4 as a novel biomarker involved in immune system response and lung adenocarcinoma progression
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Solute carrier family 4 member 4 (SLC4A4) impacts lung adenocarcinoma (LUAD) progression and immune response. High SLC4A4 expression inhibits LUAD cell invasion and enhances CD8+ T cell activity, suggesting its potential as a prognostic biomarker.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Altered solute carrier family 4 member 4 (SLC4A4) expression influences tumor cell behavior.
- The specific role of SLC4A4 in lung adenocarcinoma (LUAD) prognosis and immunotherapy remains unclear.
Purpose Of The Study
- To investigate the function of SLC4A4 in LUAD.
- To evaluate SLC4A4 as a prognostic biomarker for LUAD.
- To explore the impact of SLC4A4 on the tumor immune microenvironment.
Main Methods
- Quantitative reverse transcription-polymerase chain reaction, Western blotting, and immunohistochemistry were used to analyze SLC4A4 expression.
- Functional assays examined the effects of SLC4A4 overexpression on LUAD cell behavior.
- A prognostic risk model was developed using public databases.
- Xenograft models and flow cytometry assessed SLC4A4's role in the tumor immune microenvironment.
Main Results
- SLC4A4 upregulation inhibited LUAD cell migration and invasion while promoting apoptosis.
- A 10-gene prognostic model based on SLC4A4 expression demonstrated good predictive accuracy (AUCs ~0.72-0.73).
- High SLC4A4 expression enhanced CD8+ T cell proliferation and cytokine secretion, boosting anti-tumor immunity.
Conclusions
- SLC4A4 serves as a valuable prognostic indicator for LUAD.
- SLC4A4 modulation impacts LUAD progression and immune response.
- Findings offer new perspectives for LUAD diagnosis and treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
